Daclizumab Treatment Report

Category: Prescription Drugs

Most Popular Types: Zenapax

false

See also: MS Phase 3 Daclizumab Study DECIDE

What is Daclizumab?

An example of Daclizumab

This is an immunosuppresant, used to prevent organ rejection in kidney transplant cases. It has also been tested in clinical trials as a treatment for Multiple Sclerosis.

Reported Purpose & Perceived Effectiveness

Reasons and Perceived effectiveness
Perceived Effectiveness
Purpose # of patients # of patients with evaluations
Major
Moderate
Slight
None
Can’t tell
7 4 Efficacy_major Efficacy_slight Efficacy_cant_tell
4 2 Efficacy_major Efficacy_cant_tell
3 0

See all 8 patients currently taking Daclizumab

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
2
None
4

Commonly reported side effects, conditions, and hospitalizations associated with Daclizumab

1
1

Reported Dosages

  monthly 1 mg monthly 1 other monthly 5 mg monthly 150 mg monthly 5 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Daclizumab (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 6   Other: 67%
Did not seem to work 2   Did not seem to work: 22%
Doctor's advice 2   Doctor's advice: 22%
Course of treatment ended 1   Course of treatment ended: 11%

See all 8 patients who’ve stopped taking Daclizumab

Currently Taking Daclizumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Daclizumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Daclizumab

Always
5 83%
Usually
0 0%
Sometimes
0 0%
Never
1 17%

Burden

Difficulty being on treatment

Burden of Daclizumab

Very
0 0%
Somewhat
1 17%
A little
1 17%
Not at all
4 67%

Cost

Paid out of pocket

Cost of Daclizumab

$200+
1 33%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
2 67%

Sort by: Helpfulness | Most Recent

3 patient evaluations for Daclizumab

Purpose: Participate in clinical trial (Started Mar 03, 2007)
Date Dosage Perceived effectiveness Side Effects Adherence Burden
May 17, 2010 1 other Monthly Led_efficacy_4Led_efficacy_4Led_efficacy_4Led_efficacy_4Major MildMildMildMildMild AlwaysAlwaysAlwaysAlwaysAlways SomewhatSomewhatSomewhatSomewhatSomewhat
Apr 13, 2010 1 other Monthly Led_efficacy_4Led_efficacy_4Led_efficacy_4Led_efficacy_4Major MildMildMildMildMild AlwaysAlwaysAlwaysAlwaysAlways VeryVeryVeryVeryVery
Feb 16, 2010 1 other Monthly Led_efficacy_4Led_efficacy_4Led_efficacy_4Led_efficacy_4Major NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
Side effects:
Rash or skin problems
Date
May 17, 2010
Advice & Tips
I get MRI's every month as part of the NIH study of this drug. Once again, my April MRI showed no new lesions.
Cost
< $25 monthly
Date
Apr 13, 2010
Advice & Tips
As stated in my bio, I fly to the NIH once a month for an infusion of this drug. I receive monthly MRIs, and I hope to be getting monthly copies of the results of the MRIs and other tests to share with you. So far, there have been no new lesions popping up on my MRIs since I began taking this drug. I have been able to maintain a fairly active lifestyle. I swim 30 minutes a day, three days a week. I walk my dog at least once a day. I lift weights three days a week. I do yoga once a week. I have intermittent pain and fatigue and struggle with bladder issues; the damage from prior MS attacks has not evaporated. I am just grateful to have no new symptoms to have to cope with. I have had a pesky and persistent skin rash since starting this drug. I am unsure whether Daclizumab is to blame, or a hyperactive thyroid.
Cost
< $25 monthly
Date
Feb 16, 2010
Advice & Tips
I really hope this drug makes it onto the market. I turned to Daclizumab as an off-label treatment for MS three years ago, and as far as I know have experienced no subsequent MS attacks and no further brain lesions. Production of Daclizumab was halted in the US in September. Another pharma company is considering producing this drug in a slightly form, with a different delivery system (mine was IV.) The NIH flew me to Baltimore to screen me as a potential participant in a study of a new formulary of this drug. They also gave me what may be my last infusion if I am not included in the study. I haven't heard back from the NIH yet. Daclizumab infusions shield me from enduring the worst of my MS symptoms for about 3 weeks. Which only goes to show the drug really works. If I can't continue on the NIH study, I'm not sure what medication I'll turn to. I've already tried Avonex, and experienced bad side effects, as well as a progression of my MS, and Copaxone, which caused no side effects but did not prevent the occurrence of new lesions. People with MS need more treatment options, while we wait for a cure. For those of you out there with MS, I can attest from first hand experience that Daclizumab is safe, effective drug. The sooner it's available, the better for all of us.
Cost
< $25 monthly
  • Icon_thumb_on 1 helpful mark
  • edawgg
    Sex: F
    Data Quality: 3 stars
    MS: 11 yrs
    Type: Relapsing-Remitting
    Sensation: Mild
    Overall: None
    Cognition: mild
    Vision: none
    Speech: none
    Swallowing: none
    Upper limb: mild
    Walking: none
  • 1949-thumb
  • See edawgg's full Daclizumab history
Purpose: MS (Multiple Sclerosis) (Started Feb 06, 2008)
Date Dosage Perceived effectiveness Side Effects Adherence Burden
Feb 12, 2010 5 mg Monthly ?Can't tell NoneNoneNoneNoneNone NeverNeverNeverNeverNever Not at allNot at allNot at allNot at allNot at all
Jan 12, 2010 5 mg Monthly Led_efficacy_4Led_efficacy_4Led_efficacy_4Led_efficacy_4Major NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways A littleA littleA littleA littleA little
Date
Feb 12, 2010
Advice & Tips
i broke out in a rash 48 hours later and i had a very itchy rash for 8 weeks on my belly, arms, chest and back. i got an antibody blood test 10 weeks later and i am allergic to tysabri.
  • Icon_thumb_off 0 helpful marks
  • LSK
    Sex: F
    Data Quality: 3 stars
    MS: 20 yrs
    Type: Secondary Progressive
    Sensation: Moderate
    Overall: Moderate
    Cognition: severe
    Vision: none
    Speech: moderate
    Swallowing: moderate
    Upper limb: moderate
    Walking: moderate
  • 12214-thumb
  • See LSK's full Daclizumab history
Purpose: MS (Multiple Sclerosis) (Started May 01, 2004)
Date Dosage Perceived effectiveness Side Effects Adherence Burden
Mar 01, 2006 60 mg Monthly Led_efficacy_2Led_efficacy_2Led_defaultLed_defaultSlight NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
  • Icon_thumb_off 0 helpful marks

3 additional evaluations for Daclizumab are not currently shared publicly.

What is daclizumab?

Daclizumab is an immunosuppressant. Immunosuppressants decrease the actions of the body’s immune system.

Daclizumab is used to prevent the body from rejecting a transplanted kidney. Daclizumab is usually used as part of a treatment regimen including other medications.

Daclizumab may also be used for purposes other than those listed in this medication guide.


Precautions

Because it may cause serious side effects, daclizumab should only be prescribed by a doctor experienced in immunosuppressive therapy and the management of organ transplant patients. Discuss the risks and benefits of using this medication with your doctor.

Before using daclizumab, tell your doctor if you

  • have used daclizumab in the past;
  • have had a previous allergic reaction to daclizumab;
  • have any active or chronic viral, bacterial, or fungal infection; or
  • have a suppressed immune system or take medications that may suppress the immune system (e.g., medicines to prevent rejection of a transplanted organ, some cancer medicines, others).

You may not be able to use daclizumab, or you may require a dosage adjustment or special monitoring if you have any of the conditions listed above.

Daclizumab is in the FDA pregnancy category C. This means that it is not known whether daclizumab will be harmful to an unborn baby. Do not use this medication without first talking to your doctor if you are pregnant or could become pregnant during treatment. For women who could become pregnant, contraception is recommended before starting, during, and for four months following treatment with daclizumab to ensure protection from pregnancy.

It is not known whether daclizumab passes into breast milk. Do not use daclizumab without first talking to your doctor if you are breast-feeding a baby.

Daclizumab can lower the activity of the immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses. Contact your doctor immediately if you develop any signs of illness or infection.

Talk to your doctor before receiving any vaccines during treatment with daclizumab. Some vaccines may not be effective, or may be harmful, if received during treatment with daclizumab. In addition, avoiding close contact with people who have recently been vaccinated with a "live” vaccine (e.g. oral polio vaccine, nasal influenza vaccine) may be recommended. There is a chance that the virus can be passed on to you.

Tell your doctor and dentist that you are using this medication before having surgery and before starting any other medicines.

Back to top

Instructions

Seek emergency medical attention if an overdose is suspected.

Symptoms of a daclizumab overdose are not known.

Contact your doctor if you miss a dose of daclizumab.

Back to top

Side Effects

There may be an increased risk of infection with the use of daclizumab. Contact your doctor immediately if you develop signs of infection such as fever or chills; sore throat, coughing, congestion or other signs of infection; redness, pain, or swelling of a skin wound; or burning or difficult urination.

Treatment with an immunosuppressant such as daclizumab may increase the risk of developing certain types of cancer (e.g., lymphoma). Talk to your doctor about the risks and benefits of using this medication.

If you experience a serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives) to daclizumab, seek emergency medical attention.

Other, less serious side effects may also occur. Continue to use daclizumab and notify your doctor if you experience

  • upset stomach, nausea, or vomiting;
  • diarrhea or constipation;
  • tremor or dizziness;
  • headache; or
  • swelling of the hands, feet or legs.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.

Back to top

Interactions

Talk to your doctor before receiving any vaccines during treatment with daclizumab. Some vaccines may not be effective, or may be harmful, if received during treatment with daclizumab. In addition, avoiding close contact with people who have recently been vaccinated with a "live” vaccine (e.g. oral polio vaccine, nasal influenza vaccine) may be recommended. There is a chance that the virus can be passed on to you.

Drugs other than those listed here may also interact with daclizumab. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including vitamins, minerals, and herbal products.

Other Names

Zenapax and daclizumab

Back to top

Disclaimer

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2004 Cerner Multum, Inc. Version 2.05. Revision date 8/23/04

Last updated: